相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches
Fabio Salvatore Macaluso et al.
INFLAMMATORY BOWEL DISEASES (2021)
Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next?
Ferdinando D'Amico et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis
J. Hercogova et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
Joana Torres et al.
JOURNAL OF CROHNS & COLITIS (2020)
Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group
Ferdinando D'Amico et al.
DIGESTIVE AND LIVER DISEASE (2020)
Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre
Martin Lukas et al.
JOURNAL OF CROHNS & COLITIS (2020)
The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
Liese Barbier et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
Roy Fleischmann et al.
RHEUMATOLOGY AND THERAPY (2020)
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy
Alessandro Armuzzi et al.
INFLAMMATORY BOWEL DISEASES (2019)
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
G. L. Goll et al.
JOURNAL OF INTERNAL MEDICINE (2019)
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients
Lieven Pouillon et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease
M. Chaparro et al.
JOURNAL OF CROHNS & COLITIS (2019)
Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study
Antoine Meyer et al.
ANNALS OF INTERNAL MEDICINE (2019)
Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade
Akos Ilias et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension
Mark C. Genovese et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study
Nagesh Kamat et al.
INDIAN JOURNAL OF GASTROENTEROLOGY (2019)
SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
Joao Goncalves et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2019)
Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease
Gionata Fiorino et al.
INFLAMMATORY BOWEL DISEASES (2018)
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis Fifty-Two-Week Phase III Randomized Study Results
Michael E. Weinblatt et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study
E. M. H. Schmitz et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations
Laurent Peyrin-Biroulet et al.
JOURNAL OF CROHNS & COLITIS (2017)
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update
Silvio Danese et al.
JOURNAL OF CROHNS & COLITIS (2017)
Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort
Lorant Gonczi et al.
INFLAMMATORY BOWEL DISEASES (2017)
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar
Gionata Fiorino et al.
INFLAMMATORY BOWEL DISEASES (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2017)
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany
Emma Sullivan et al.
PLOS ONE (2017)
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
Stanley Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey
Silvio Danese et al.
JOURNAL OF CROHNS & COLITIS (2016)
Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis
Klaudia Farkas et al.
JOURNAL OF CROHNS & COLITIS (2016)
Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
Evelien Moorkens et al.
FRONTIERS IN PHARMACOLOGY (2016)
A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study
Dae Hyun Yoo et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study
Won Park et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF alpha therapy: results from the COIN study
Mirthe Emilie van der Valk et al.
GUT (2014)
Biosimilars in Oncology: From Development to Clinical Practice
Katherine H. Rak Tkaczuk et al.
SEMINARS IN ONCOLOGY (2014)
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
